IMARC Group has recently released a new research study titled “Mexico Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
Market Overview
The Mexico Cancer Immunotherapy Market size reached USD 1.55 Billion in 2024 and is forecasted to reach USD 3.51 Billion by 2033. This represents a compound annual growth rate (CAGR) of 8.50% during the forecast period of 2025 to 2033. The market growth is driven by the increased adoption of checkpoint inhibitors, expanded use of cancer vaccines, and diversified roles of immunomodulators across various cancer types. As these immunotherapy treatments become part of national oncology standards in Mexico, the market continues to grow steadily and strategically.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Mexico Cancer Immunotherapy Market Key Takeaways
- Current Market Size: USD 1.55 Billion (2024)
- CAGR: 8.50% (2025-2033)
- Forecast Period: 2025-2033
- The growing use of checkpoint inhibitors, especially for melanoma and non-small cell lung cancer, is a key driver in Mexico, with public and private healthcare facilities adopting these therapies as routine protocols.
- Clinical trials of CAR-T cell therapy for blood cancers have commenced in Mexico, enhancing treatment options.
- Cancer vaccine applications are expanding beyond cervical and liver cancers to lung and colorectal cancers, supported by increased investments and research.
- The use of immunomodulators is diversifying across breast, prostate, and head and neck cancers, with new biosimilars and therapies broadening options.
- Immunotherapies are increasingly integrated into multimodal treatment regimens and national treatment guidelines.
Sample Request Link: https://www.imarcgroup.com/mexico-cancer-immunotherapy-market/requestsample
Market Growth Factors
The rising use of checkpoint inhibitors in Mexico is a critical driver of market growth. These inhibitors are effective against various cancers such as melanoma and non-small cell lung cancer by enhancing the immune system’s ability to recognize and destroy cancer cells. Both public and private healthcare providers have integrated checkpoint inhibitor therapies into standard treatment protocols, reflecting a shift towards personalized medicine and immune-based regimens. Patients resistant to conventional treatments like chemotherapy and radiation are increasingly receiving these therapies, propelling market expansion with growing patient demand and medical awareness.
In March 2023, Mexico initiated CAR-T cell therapy clinical trials for blood cancers at Dr. José Eleuterio González Hospital in collaboration with ImmunoACT, the National Polytechnic Institute, and the Salvador Zubirán Institute. This advancement, along with enhanced diagnostic technologies and biomarker testing availability, facilitates rational therapy use and supports guideline inclusion, further transforming the cancer treatment landscape and fostering market growth.
Cancer vaccines are steadily gaining prominence through increased investments focusing on prevention and therapeutic immunization. Initially targeting cervical and liver cancers, vaccine research has extended to lung and colorectal cancers to induce durable immune memory against tumor antigens. Health authority programs and educational campaigns boost awareness and early diagnosis, critical for vaccine success. Ongoing trials investigate vaccine effectiveness alongside other immunotherapies, indicating policy support for advanced oncology care and accelerating immunotherapy development in Mexico.
Immunomodulators also contribute to market growth as they are increasingly used across diverse cancer forms, including breast, prostate, and head and neck cancers. Recent introductions like Zydus Lifesciences' Bevacizumab biosimilar and new treatments from CHIPSA and Immunocine provide broader therapy choices. These drugs are integrated into multimodal treatments with surgery, chemotherapy, and radiation to overcome resistance. Advances in tumor microenvironment understanding allow for improved selective applications and combination therapies. Their clinical uptake and inclusion in treatment guidelines underscore their growing market importance.
Market Segmentation
Therapy Type Insights:
- Monoclonal Antibodies: Not provided in source.
- Cancer Vaccines: These are expanding in use for prevention and treatment, explored beyond cervical and liver cancers to lung and colorectal cancers, driven by investments and research.
- Checkpoint Inhibitors: Widely adopted for treating melanoma and non-small cell lung cancer, they optimize immune response to destroy cancer cells, increasingly forming part of routine clinical protocols.
- Immunomodulators: Utilized across multiple cancers including breast, prostate, and head and neck cancers, often combined with other treatments to modulate immune function and improve outcomes.
- Others: Not provided in source.
Application Insights:
- Lung Cancer: Targeted by checkpoint inhibitors and vaccines under investigation.
- Breast Cancer: Increasing use of immunomodulators.
- Colorectal Cancer: Cancer vaccines are entering investigative stages.
- Melanoma: Effectively treated by checkpoint inhibitors.
- Prostate Cancer: Use of immunomodulators is growing.
- Head and Neck Cancer: Immunomodulators are diversifying treatment options.
- Others: Not provided in source.
End User Insights:
- Hospitals: Major users of immunotherapy treatments.
- Cancer Research Centers: Active in clinical trials and development of therapies.
- Clinics: Provide immunotherapy services and patient care.
- Others: Not provided in source.
Regional Insights
The Mexico Cancer Immunotherapy Market segments the regions as Northern Mexico, Central Mexico, Southern Mexico, and Others. Specific statistics such as regional market shares or CAGR by region are not provided in the source. Hence, the dominant region is not explicitly identified, and no quantitative regional insights are available.
Recent Developments & News
In February 2025, Astellas and Pfizer announced the long-term results of the Phase 3 EV-302 trial for PADCEV® (enfortumab vedotin) plus KEYTRUDA® (pembrolizumab). The combination showed significantly greater efficacy as a first-line therapy for locally advanced or metastatic urothelial cancer, dramatically improving progression-free and overall survival. This outcome established the combination as a new standard of care in Mexico.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302